「code」の検索結果
18件：11～15件目を表示
-
tarted Phase III clinical trials in Japan for an in-house developed compound having the development code SJP-0008. Central Retinal Artery Occlusion (CRAO), the therapeutic target of SJP-0008, occurs w...
https://www.senju.co.jp/system/files/content_news/2024-05/ENG_20240509.pdf -
tarted Phase III clinical trials in Japan for an in-house developed compound having the development code SJP-0008. Central Retinal Artery Occlusion (CRAO), the therapeutic target of SJP-0008, occurs w...
https://www.senju.co.jp/system/files/content_news/2024-05/ENG_20240509_0.pdf -
sed to announce that “Avarept® Ophthalmic suspension 0.3%” (Generic Name: Motugivatrep, development code: SJP-0132, hereinafter: Product), discovered and licensed by Mochida Pharmaceutical Co., Ltd. (...
https://www.senju.co.jp/system/files/content_news/2025-12/ENG_20251222_0.pdf -
Compliance System | Our Initiatives for Society/Environment | About Senju | SENJU Pharmaceutical
Code of Conduct for Compliance The directors, employees and other members of Senju Pharmaceutical Co., Ltd. (“SENJU”) will act in compliance not only with the law but will operate under a high standar...
https://www.senju.co.jp/english/about/csr03.html -
事業所・子会社一覧 | 企業情報 | 千寿製薬株式会社
, World Financial Centre No.1, East 3rd Ring Middle Road, Chaoyang District, Beijing, P.R.C. Postal Code：100020 Tel：+86-10-6533-0200 Fax：+86-10-6536-1329 千寿製薬 ハノイ事務所 SENJU PHARMACEUTICAL CO., LTD. Han...
https://www.senju.co.jp/about/office/